Feature | April 06, 2011

Promus Element Comparable to Leading Drug-Eluting Stent

April 6, 2011 – One-year results from the pivotal PLATINUM Workhorse trial were presented at the American College of Cardiology (ACC) Scientific Session in New Orleans. The trial compared the safety and effectiveness of Boston Scientific’s Promus Element everolimus-eluting platinum chromium (PtCr) coronary stent to the Promus everolimus-eluting coronary stent.

The trial demonstrated the clinical non-inferiority of the Promus Element in comparison to the Promus in treating de novo coronary artery lesions, while showing a procedural benefit of reduced rates of unplanned (bail-out or emergency) stenting.

Results were presented by Gregg W. Stone, M.D., professor of medicine and director of research and education at the Center for Interventional Vascular Therapy at Columbia University Medical Center/New York-Presbyterian Hospital and global principal investigator of the trial. Results were also published concurrently in the online version of the Journal of American College of Cardiology (JACC) and will be available in the April 19 print edition.

"The Promus Element platinum chromium stent met the primary non-inferiority endpoint of target lesion failure at one year compared to the Promus stent, while demonstrating excellent safety and effectiveness with low rates of cardiac death, myocardial infarction, stent thrombosis and revascularization," Stone said. "The remarkably low rates of stent thrombosis and target lesion revascularization at one year confirm the successful transfer of the favorable outcomes associated with everolimus to the novel platinum chromium stent design."

The primary endpoint of non-inferiority for the Promus Element stent compared to the Promus stent was met with a 12-month target lesion failure (TLF) rate in the per protocol population of 3.4 percent versus 2.9 percent, respectively (pNI=0.001). No statistically significant differences in TLF components were observed between the two stents. In the intention-to-treat population, TLF (3.5 percent vs. 3.2 percent, p=0.72), cardiac death related to the target vessel (0.8 percent vs. 0.4 percent, p=0.51), myocardial infarction (MI) related to the target vessel (0.8 percent vs. 1.6 percent, p=0.14) and ischemia-driven target lesion revascularization (TLR, 1.9 percent vs. 1.9 percent, p=0.96) were all similar. Low rates of target vessel revascularization (TVR, 2.7 percent vs. 2.9 percent, p=0.83) and stent thrombosis (ARC definite/probable, 0.4 percent vs. 0.4 percent, p=0.99) were also observed at 12 months for the Promus Element and Promus stents.

Both stents achieved high rates of technical success (99.4 percent for Promus Element vs. 98.8 percent for Promus, p=0.14) indicating successful delivery and deployment of the stent to the target vessel. The Promus Element achieved a significant reduction in unplanned (bail-out or emergency) stenting (5.9 vs. 9.8 percent, p=0.004), including a significantly lower rate of inadequate lesion coverage (1.4 vs. 3.4 percent, p=0.01). These clinical observations are consistent with the results of comparative bench and animal studies, which have demonstrated the enhanced visibility of the Promus Element relative to the Promus.

The Promus Element received CE mark approval and was launched in Europe and other international markets in 2009. It features a PtCr alloy and new stent design to offer greater strength, enhanced deliverability and good visibility. The thin-strut stent is designed for improved conformability, minimal recoil and uniform lesion coverage and drug distribution. The advanced low-profile delivery system facilitates precise delivery of the stent across challenging lesions.

The PLATINUM clinical program is evaluating the safety and effectiveness of the Promus Element stent in five multi-center studies totaling more than 1,800 patients, including single-arm studies evaluating small vessels, long lesions, pharmacokinetics, and quantitative coronary angiography and intravascular ultrasound data. PLATINUM Workhorse is a global, randomized, pivotal controlled trial designed to support U.S. Food and Drug Administration (FDA) approval of the Promus Element. The trial enrolled 1,530 patients with up to two de novo lesions at 132 sites worldwide, and completed enrollment in September 2009.

For more information: www.bostonscientific.com

Related Content

Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
St. Jude Medical, Amplatzer Amulet LAA Occluder, observational study, TCT 2016
News | Left Atrial Appendage (LAA) Occluders| November 03, 2016
St. Jude Medical Inc. presented favorable results from the largest observational study to date of the company’s...
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery| November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
News | Drug-Eluting Balloons| November 03, 2016
The Spectranetics Corp. announced that it has submitted to the U.S. Food & Drug Administration (FDA) its Pre-Market...
Medtronic, Resolute Integrity DES, drug-eluting stent, BIO-RESORT study, TCT 2016
News | Stents Drug Eluting| November 02, 2016
Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing the first all-comers...
Medtronic, Harmony TPV, transcatheter pulmonary valve, clinical study results, TCT 2016
News | Heart Valve Technology| November 02, 2016
Medtronic plc recently announced new clinical data for the Harmony Transcatheter Pulmonary Valve (TPV) from its early...
Medtronic, Drug-Filled Stent, DFS, RevElution trial, first clinical data, TCT 2016, Stephen Worthley
News | Stents Drug Eluting| November 01, 2016
November 1, 2016 — Medtronic plc unveiled the first clinical outcomes of its novel...
Edwards, Sapien transcatheter heart valve, PARTNER trial, five-year echo data, TCT 2016
News | Heart Valve Technology| November 01, 2016
Edwards Lifesciences Corp. announced new five-year hemodynamic data from the PARTNER Trial demonstrating excellent...
Medtronic, CoreValve Evolut R TAVR system, TCT 2016, FORWARD Study, STS/ACC TVT Registry
News | Heart Valve Technology| October 31, 2016
Medtronic plc presented new positive data from two large registries aimed at evaluating 30-day clinical performance...
Overlay Init